Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 4.8 RMB per 10 shares (including tax) based on a total of 288,000,000 shares[3]. - The company approved a cash dividend of RMB 4.00 per 10 shares, totaling RMB 96,000,000.00, and a capital reserve increase of 2 shares for every 10 shares held[145]. - The company reported a positive profit available for distribution to shareholders but did not propose a cash dividend distribution plan[147]. - The company reported a commitment to strictly adhere to the profit distribution policy as per legal and regulatory requirements, ensuring investor returns[189]. - The profit distribution policy is designed to be long-term effective and is currently being implemented normally[190]. - The company has agreed to the content of the "Three-Year Dividend Return Plan" approved by the board and shareholders[190]. - The company committed to ensuring investor returns through strict adherence to profit distribution policies and relevant regulations[191]. - The company reported a profit distribution plan that aligns with its long-term profit distribution policy, which was approved by the board and shareholders[192]. Financial Performance - The company's operating revenue for 2023 reached ¥663,025,874, representing a 28.76% increase compared to ¥514,911,768 in 2022[22]. - Net profit attributable to shareholders was ¥176,116,201, a 40.00% increase from ¥125,723,912 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥170,236,321, reflecting a 42.13% increase from ¥119,704,115 in 2022[22]. - Basic and diluted earnings per share increased to ¥0.61, up 38.64% from ¥0.44 in 2022[22]. - The total revenue for the reporting period was ¥663,025,874.35, reflecting a year-on-year growth of 28.76%[41]. - The net profit attributable to shareholders was ¥176,116,201.67, representing a 40.00% increase from the previous year[41]. - Sales revenue from active pharmaceutical ingredients (APIs) was ¥554,613,468.87, up 29.92% year-on-year, while formulation sales revenue surpassed ¥100 million for the first time, growing by 19.56%[41]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a year-over-year growth of 15%[186]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in the future development outlook section[3]. - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the CEO and accounting head[3]. Research and Development - The company emphasizes R&D in new technologies and products, having undertaken several provincial scientific research projects[37]. - The company's R&D investment reached ¥52,774,555.54, a significant increase of 165.94% compared to the previous year[40]. - The number of R&D personnel increased by 18.02% to 131 in 2023, with a higher proportion of staff holding bachelor's degrees (43.14% increase) and master's degrees (57.14% increase)[63]. - The company is actively developing new formulations and improving existing processes to enhance production efficiency and reduce costs[43]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[186]. - The company plans to invest 150 million yuan for the development of new technologies and products[186]. Market Expansion - The company is positioned to benefit from the ongoing reforms in the healthcare system, which aim to promote high-quality development in the pharmaceutical sector[34]. - The company aims to expand its market presence by leveraging its established brand reputation to attract new clients domestically and internationally[90]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market penetration by the end of 2024[122]. - Market expansion plans include entering two new provinces, aiming to increase market share by 5% in the next year[186]. Governance and Compliance - The company maintains a complete and independent asset structure, with no instances of fund occupation by the controlling shareholder during the reporting period[104]. - The management team operates independently, with all key executives exclusively working for the company and not holding positions in related parties[106]. - The company has established a robust financial accounting system, ensuring independent financial decision-making and compliance with accounting standards[108]. - The company has a clear governance structure that complies with legal requirements, ensuring effective decision-making and oversight[104]. - The company has not engaged in any related party transactions that could lead to unfair competition during the reporting period[110]. - The company has established measures to reduce and regulate related party transactions, ensuring transparency and compliance with legal requirements[195]. Environmental Responsibility - The company has invested a total of 11.04 million yuan in environmental governance during the reporting period[174]. - The wastewater treatment facility has a capacity of 3,000 tons per day, and all monitored pollutants met the standards without any exceedance during the reporting period[164][171]. - The company has a waste gas treatment facility with a capacity of 260,000 cubic meters per hour, employing various technologies to ensure compliance with emission standards[165][170]. - The company has implemented measures to reduce carbon emissions, including energy management and the use of energy-efficient equipment[175]. - The company has established a hazardous waste management plan and complies with regulations for hazardous waste disposal[173]. - The company prioritizes environmental protection and sustainable development, implementing advanced eco-friendly technologies and optimizing energy structures to reduce emissions and improve resource efficiency[179]. Employee Relations - The company is committed to providing a good working environment and career development opportunities for employees, adhering to labor laws and focusing on employee health and satisfaction[177]. - The company conducted various employee training programs, including safety production and quality training, to enhance employee skills and capabilities[143]. - The company reported a total of 1,012 employees at the end of the reporting period, with 692 in production, 20 in sales, 149 in technology, 19 in finance, and 132 in administration[141]. Shareholder Engagement - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal regulations and providing equal rights to all shareholders[97]. - The company has provided opportunities for minority shareholders to express their opinions and protect their legal rights[147]. - The management team is committed to transparency and regular communication with shareholders regarding company performance and strategic initiatives[115].
亨迪药业(301211) - 2023 Q4 - 年度财报